The official blog of the Lung Institute.

Cellular Treatment Therapy vs. Lung Transplant

22 Nov 2014
| Under Lung Transplant, Treatments | Posted by
| 1 Comment
Cellular Therapy vs. Lung Transplant Lung Institute

Lung transplants are often recommended to individuals in the last stage of their disease. In most situations, a lung transplant is prescribed to a person when it is suspected that they will not survive another year.

Typically, good candidates for a lung transplant are in their 40s or younger and in good health, with the exception of the lungs. Historically, people above the age of 60 were denied candidacy for lung transplant surgery as the risks increase as you age. However, at certain institutions lung transplants are being performed on individuals in their 70s. Under the right circumstances, Johns Hopkins Medicine is one provider.

At the Lung Institute, we see a lot of patients that have been denied the opportunity for a lung transplant either because of other health concerns or because they are too old. Others don’t want to endure the surgery or the risks. So what really are the pros and cons of cellular therapy vs. lung transplant?

Cellular Therapy vs. Lung Transplant

According to the National Institutes of Health (NIH), here are some statistics on life expectancy for lung transplant patients:

  • Approximately 4 out of 5 people are still alive 1 year after a single/double lung transplant.
  • Approximately 2 out of 5 transplant recipients are alive at 5 years.
  • Rejection is the highest risk for mortality after a transplant. Anti-rejection drugs must be taken every day to reduce this risk. Since these drugs suppress the immune system, they can leave individuals more susceptible to infection.
  • Outcomes are similar for single and double lung transplants.
  • Five years after a transplant approximately 1 in 5 people develop cancer or a heart condition.

Both cellular therapy and a lung transplant have been proven to significantly improve sufferers’ quality of life. Unlike a lung transplant, cellular therapy does not have a long list of risk factors. More and more people are opting to undergo cellular therapy either before a lung transplant to reduce the likelihood of needing one, or as an alternative to lung transplant surgery. The important thing to know is that you do have options. If your physician tells you that you can’t have a lung transplant it does not have to be the end of your treatment journey.

You Have Options

If you or a loved one has been found ineligible for a lung transplant, cellular therapy can help. Cellular therapy in no way reduces the need for a transplant, but it can significantly improve your quality of life. The great thing about cellular therapy is that it can be prescribed to individuals that have just been diagnosed as well as those people in the final stages of their disease.

Progress milestones differ from patient to patient, but at the Lung Institute, what we hear over and over are things like, “It used to take me an hour to take a shower, and now it takes me a normal 15 minutes.” Read our testimonials to find out more.

How it Works

We have harnessed the natural healing capacity of a person’s cells. Our treatment utilizes autologous cells, meaning cells from the patient’s own body. Hence, our procedures are considered safe and effective with zero chance of rejection from the body.

The treatment process occurs over the course of 3 days with each office visit lasting only a few hours.  Since this treatment is minimally invasive, and the post treatment downtime is significantly less than that of a transplant, many individuals are turning to cellular therapy for treatment.

Patients that have been treated at the Lung Institute are walking further, depending on supplemental oxygen less, and breathing easier.  As more patients see consistent positive results, we suspect that a greater number of people will utilize cellular therapy before going under the knife for a transplant.

If you or a loved one has COPD or other lung disease and want to learn more about treatment options, contact us or call 888-745-6697.


* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.